Drug Trial Radar · NCT06453213
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
49
Actual
Start
Oct 14, 2024
Primary completion
May 26, 2027
Study completion Jul 9, 2027
Sponsor
- Lead sponsor
- SK Life Science, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagnosed or recurrent POS/focal onset epilepsy.
Conditions
- Focal Onset Seizure
Interventions
CenobamateDrug
The 100 mg/ day Treatment Period includes a 6-week Titration Phase and a 26-week Maintenance Phase. During the Titration Phase subjects will be treated with cenobamate 12.5 mg/day for two weeks, 25 mg/day for two weeks and 50 mg/day for two weeks. Subjects tolerating cenobamate at the end of the Titration Phase will continue treatment with 100 mg/day in the Maintenance Phase for 26 weeks. If the subject does not experience a certain type of seizure in the 100 mg/day Maintenance Phase, he/she can enter the Optional Extension Period (100 mg/day). The 200 mg/day treatment period consists of a 2-week Titration Phase and a 26-week Maintenance Phase. During the 2-week Titration Phase, subjects will receive cenobamate 150 mg/day before entering the 26-week 200 mg/day Maintenance Phase. If the subject does not experience a certain type of seizure during the 200 mg/day Maintenance Phase, he/she can enter the 26 week Optional Extension Period (200 mg/day).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seizure-freedom during the 26-week Maintenance Phase of the 100 mg/day Treatment PeriodTime frame: 32 weeks
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Arizona Neuroscience Research
Phoenix, Arizona
Center For Neurosciences
Tucson, Arizona
Clinical Trials Inc
Little Rock, Arkansas
Neuro Pain Medical Center
Fresno, California
Hoag Physician Partners
Newport Beach, California
Hartford Hospital
Hartford, Connecticut
Yale School of Medicine - Yale-New Haven Hospital
New Haven, Connecticut
Elite Clinical Research
Miami, Florida
Knight Neurology
Rockledge, Florida
Consultants In Epilepsy and Neurology
Boise, Idaho
Bluegrass Epilepsy Research LLC
Lexington, Kentucky
Louisiana State University Health Sciences
Shreveport, Louisiana
John Hopkins Epilepsy Center
Baltimore, Maryland
Henry Ford Health System
Detroit, Michigan
Wayne Neurology PLC
Plymouth, Michigan
University of Missouri Health Care
Columbia, Missouri
NY Neurology Associates
New York, New York
Mount Sinai Hospital
New York, New York
DHR Health Institute for Research and Development
Edinburg, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.